Call for standards of epigenetic data

02-Oct-2018 - At the heart of every cell is the nucleus, which acts as the cell’s control center. Recent studies have revealed more and more information about its organization and dynamics. However, the rapid development of methods and the increasing complexity of the collected data pose major challenges. ...

At BfR consumer health protection is in good hands: BfR certified in accordance with DIN EN ISO 9001: 2008

27-Aug-2010 - The Federal Institute for Risk Assessment (BfR) is the first federal authority to introduce a quality management system (QM system) for all its work areas that has been audited by TÜV Nord and certified in accordance with ISO 9001. The Vice-President of BfR, Professor Dr. Reiner Wittkowski, was ...

BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility

23-Oct-2009 - BioStorage Technologies, Inc. will expand its European operations with the opening of a new 16,140 square foot (1,499 sq meters) full-service biorepository in Frankfurt, Germany. BioStorage Technologies’ expanded European operations is part of the company’s strategic growth plan to accommodate a ...

Trenzyme receives ISO 9001 certification

01-Oct-2009 - The Trenzyme GmbH has set another milestone as a first class service provider for the pharma and life science industry. By obtaining the DIN EN ISO 9001:2008 certification the German "TÜV Süd" agency officially acknowledged Trenzyme's high quality management standards. Trenzyme becomes one of few ...

Lonza and LFB Enter Manufacturing Agreement

15-Jul-2009 - Lonza and LFB announced the signing of an agreement to manufacture a monoclonal anti-RhD antibody developed by LFB. Under this agreement, the process developed by LFB will be transferred to Lonza which will provide GMP manufacturing services for supporting the phase III clinical program. Lonza, ...

MorphoSys Achieves Clinical Milestone and Payment in Antibody Alliance

08-May-2009 - MorphoSys AG announced that it has received a milestone payment from its collaboration with Novartis. The payment was triggered by Novartis filing of the necessary documentation to initiate a Phase 1 clinical trial with a HuCAL-derived fully human antibody. This is the second HuCAL antibody to ...

The Need for Safe and Affordable Biopharmaceuticals Drives the Development of the European Biosimilars Market

24-Mar-2009 - Despite the initial regulatory hiccups, the number of biosimilars in the European market is set to increase gradually. The patent expiry of key biopharmaceuticals has opened up numerous lucrative market opportunities, while driving the development of biosimilars. In addition, payers’ perception ...

AnaSpec Establishes New Dedicated GMP Manufacturing Facility

18-Nov-2008 - In response to increased demand for GMP peptide production, AnaSpec has established a new facility dedicated to GMP manufacturing. Located adjacent to its current San Jose, California-based headquarters, the expansion provides an additional 5000 sq. ft. of dedicated GMP space including two class ...

“Two in One” enzyme: unusually flexible Scientists from the RUB have solved the structure of a viral protein

The Journal of Biological Chemistry has ranked this documentation as “Paper of the Week.”

09-Oct-2008 - A virus that infects the marine cyanobacterium Prochlorococcus can produce specific pigments more effectively than its host can. It requires only one enzyme, in contrast to the host Prochlorococcus, which needs two enzymes. The virus makes use of phycoerythrobilin synthase, a “two in one” enzyme. ...

Metvixia and Aktilite CL128 approved by FDA

30-Jun-2008 - Photocure ASA announces that Metvixia(TM) in combination with Aktilite® CL128, the LED based narrow band (630 nm) red light technology device has been approved by US Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK), a pre-cancerous skin lesion. The supplement to the ...